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Molecular-genetic characterization and rescue of a
TSFM mutation causing childhood-onset ataxia and
nonobstructive cardiomyopathy
Sonia Emperador1,2,3,8, M Pilar Bayona-Bafaluy1,3,8, Ana Fernández-Marmiesse2,4,8, Mercedes Pineda2,5,
Blanca Felgueroso6, Ester López-Gallardo1,2,3, Rafael Artuch2,5, Iria Roca4, Eduardo Ruiz-Pesini1,2,3,7,
María Luz Couce2,4 and Julio Montoya*,1,2,3
Oxidative phosphorylation dysfunction has been found in many different disorders. This biochemical pathway depends on
mitochondrial protein synthesis. Thus, mutations in components of the mitochondrial translation system can be responsible for
some of these pathologies. We identified a new homozygous missense mutation in the mitochondrial translation elongation factor
Ts gene in a patient suffering from slowly progressive childhood ataxia and hypertrophic cardiomyopathy. Using cell, biochemical
and molecular-genetic protocols, we confirm it as the etiologic factor of this phenotype. Moreover, as an important functional
confirmation, we rescued the normal molecular phenotype by expression of the wild-type TSFM cDNA in patient’s fibroblasts.
Different TSFM mutations can produce the same or very different clinical phenotypes, going from abortions to moderately severe
presentations. On the other hand, the same TSFM mutation can also produce same or different phenotypes within the same
range of presentations, therefore suggesting the involvement of unknown factors.
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INTRODUCTION
The oxidative phosphorylation system (OXPHOS) is a biochemical
pathway involved in many key cellular processes. This system includes
electron transport chain respiratory complexes I–IV (CI–CIV) and
ATP synthase (CV). OXPHOS complexes contain 13 mitochondrial
DNA (mtDNA)-encoded polypeptides. Moreover, mtDNA codes for
22 transfer and 2 ribosomal RNAs required for the expression of these
polypeptides. Mitochondrial translation also depends on many nuclear
DNA-encoded proteins. Mutations in many of these translation
components are associated to different pathologic conditions.1
CASE REPORT
The patient is a 23-year-old male born at term from non-consan-
guineous Galician parents. Ethical approval was obtained from
involved Institutional Review Boards. Written informed consents from
the patient and the family members were also obtained. He has an
elder healthy sister and his mother suffered three abortions prior to
her pregnancy. Pregnancy and delivery were uneventful with normal
early psychomotor development. Since the age of 6 years, gross- and
fine-motor clumsiness, tiptoe gait and frequent falls were observed.
Two years later, lack of coordination and reduction of visual acuity
with poor school performance were detected. Brain MRI was then
normal. A nonobstructive hypertrophic cardiomyopathy without
functional repercussion was found at 11 years old. Dystonic move-
ments in hands appeared, and progressively facial and upper-limb
dystonia with increasing clumsiness and dysarthric speech emerged at
14 years old. Metabolic screening, lactate in blood and CSF were
normal. Brain MRI showed signal intensity mainly on both lenticular
nuclei, and to a lesser extent, in the right caudate nucleus (in T2-
weighted images). Electromyography was normal. By electroneuro-
graphy, the lower limbs’ motor conduction velocity was normal and
sensory amplitude decreased. Disintegration of somatosensory-evoked
potentials of lower extremities was also observed. At present, he has
stable hypertrophic cardiomyopathy on medication, normal cognitive
function, axial ataxia with dysarthric speech, mild optic atrophy, and
frequent dystonic movements in his face, neck and shoulder region.
A muscle biopsy at the age of 16 showed red granular material with
Gomori trichrome staining, and measurements of electron transport
chain enzyme activities by spectrophotometry showed partial CI and
almost complete CIV deficiencies, with increment in CII activity.
RESULTS
To confirm this biochemical defect, we analyzed the BN-PAGE in-gel
activity in muscle and skin fibroblasts.2 An almost complete absence of
muscle CI, CIV and CV in-gel activity was observed (Figure 1a).
Moreover, CV sub-complexes were also detected. A moderate increase
in CII in-gel activity corroborated the spectrophotometric result
described in the case report. Although less pronounced than muscle
fibers, cultured fibroblasts also showed a defect in CI, CIV and CV in-
gel activities (Figure 1a).
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This deficiency in several OXPHOS complexes with mtDNA-
encoded subunits suggested a defect on the organelle genome. DNA
of all available family members was isolated from peripheral white
blood cells and from the patient muscle. However, mtDNA depletion
and mutations were ruled out. Simultaneous sequencing in MiSeq
platformQ5 (Illumina) of the coding regions of 150 nuclear genes for
mitochondrial proteins previously associated with OXPHOS defects
was performed after an in-solution hybridization enrichment method
with a custom Sure Select XT kit (Agilent). A heterozygous variant
[c.385C4T (p.(Pro129Ser))] in the NDUFS1 gene (NG_009248.1;
NM_005006.6; NP_004997.4) was observed. We also found a
c.719G4C homozygous transversion in TSFM gene (OMIM
*604723; NG_016971.1; GRCh38 Chr12:57,796,324; NM_005726.5)
exon 6 (Figure 1b). This exon, numbered like in Ahola et al,3 was also
amplified and resequenced using the Sanger method in both parents
and a healthy sister, and the change was found heterozygous. This
variant (http://databases.lovd.nl/shared/individuals/00063251) has
been previously reported only once in SNPdb (http://www.ncbi.nlm.
nih.gov/projects/SNP/rs750799705, 11 September 2015) in a Galician
heterozygous individual (http://www.ciberer.es/bier/CSVS/).
The c.719G4C variant is predicted to change a cysteine to serine at
amino acid position 240 of the EFTs protein (NP_005717.3), that is
conserved in 99 (63.9%) out of 155 animal species analyzed
(GenBank, 11 September 2015; Supplementary Figure S1). The
three-dimensional structure of the bovine elongation factor Tu
(EFTu)–EFTs dimer (PDB 1XB2)4 was obtained with the Q6RasMol
2.6 program. The cysteine 240 is located in EFTs subdomain C β5
strand from the core domain. This subdomain interacts with
the domain III of mitochondrial translation EFTu. However, the
(p.(Cys240Ser)) substitution is positioned in the other side of the
β-sheet and it does not affect the contact surface with EFTu
(Figure 1c). Western blots Q7for these proteins were performed using
anti-TSFM (EFTs) (1:1000, Q8AV38672, Sigma), anti-TUFM (EFTu)
(1:1000, SAB1406560, Sigma) and anti-actin (1:2000, A2066, Sigma) as
primary antibodies.5 This mutation provokes an important decrease in
the EFTs levels, but the EFTu amount is not affected (Figure 1d). A
mitochondrial protein synthesis analysis6 also showed an important
decrease in the levels of mtDNA-encoded polypeptides (Figure 1e).
To confirm that this TSFM mutation was responsible of the
phenotype, we tried to recover the mitochondrial translation capacity
by transfecting mutant fibroblasts with the human wild-type TSFM
cDNA (Supplementary Figure S2). These cell lines were grown in
high-glucose (25 mM) DMEM supplemented with fetal bovine serum
10%. CI and CII in-gel activities were determined (Figure 2a).
Compared with wild-type fibroblasts, CI/CII ratios were decreased
in mutant fibroblast, both in transfected and untransfected cells. To
make cells more dependent on OXPHOS function,7,8 fibroblasts were
grown in DMEM-no glucose supplemented with galactose (5 mM) and
fetal bovine serum 10%. In galactose medium, CI/CII ratios were also
decreased in mutant cells, but they were partially recovered in
Figure 1 OXPHOS characteristics. (a) OXPHOS complex (CI, CII, CIV and CV) in-gel activities from muscle and fibroblasts of patient (P) and control (C).
Asterisks indicate CV sub-complexes. (b) TSFM cDNA sequence obtained by Sanger method. (c) Structural modeling of EFTu–EFTs dimer. The locations of
EFTs amino acids that have been previously associated with missense pathologic mutations are showed in yellow color, and the new one, here reported, is
shown in red color. (d) EFTs and EFTu immunoblots. (e) Mitochondrial translation products. Gels show loading controls (right) and electrophoretic patterns of
mitochondrial translation products (left) from patient (P) and control (C) fibroblasts. Gels of this figure have been cropped to improve the clarity and
conciseness of the presentation. See Supplementary Figure S3 for uncropped gel images.
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transfected cells (Figure 2b). EFTs transfection does not increase CI
activity in transfected control fibroblasts grown in high-glucose or
galactose medium. Because this transfection does not have effect on
mutant fibroblasts grown in glucose medium, the partial recovery of
CI activity in transfected mutant fibroblasts grown in galactose
medium seems to be a specific effect. In high-glucose, wild-type and
mutant cells obtain energy from glycolysis. In galactose, CI activity will
not largely change in control cells because they are able to obtain
energy in an efficient way. On the contrary, mutant cells will not fulfill
energy requirements, and mitochondrial signals will be generated to
increase mitochondrial biogenesis and CI activity. The in-gel activity
technique is only semiquantitative. When a quantitative method
(ELISA) for CIV determination was applied,6 a significant decrease
in CIV activity and quantity was observed in mutant fibroblasts
(Figure 2c). Interestingly, the wild-type EFTs overexpression in
mutant fibroblasts recovers CIV activity and quantity (Figure 2c),
and p.MT-CO1 levels (Figure 2d), a CIV subunit involved in CIV
assembly and activity. Moreover, and taking into consideration the
loading control, the levels of other mtDNA-encoded polypeptides also
seem partially recovered (Figure 2e).
DISCUSSION
Massive sequencing approaches have largely increased the possibility of
false diagnoses, that is, the consideration of a non-disease-causing
variant as a pathogenic mutation. These errors would make difficult
the identification of the real disease causations and would have a huge
Figure 2 Wild-type EFTs overexpression (+EFTswt) in patient fibroblasts recovers OXPHOS parameters. CI and CII in-gel activities from control (C) and patient
(P) fibroblasts grew in high-glucose (25 mM) (a) and galactose (5 mM) medium (b). The control CI/CII ratios are considered 100%. (c) CIV activity/citrate
synthase activity (CIV act/CS) and CIV quantity/CS activity (CIV qua/CS) ratios. Dot line represents mean values of untransfected and transfected control
fibroblasts. Bars indicate the mean values (and SDs, n=3) of untransfected (P) and transfected (P+EFTsWT) mutant fibroblasts. Asterisks denote statistically
significant P-values (mutant vs control) (unpaired t-test) (d) p.MT-CO1 immunoblot. An immunoblot for the nDNA-encoded CII subunit, SDHA, is also shown
as a loading control. EFTs immunoblots confirm the overexpression of this translation factor in the transfected cells. Rho0 indicates cells with no mtDNA and,
therefore, without the mtDNA-encoded p.MT-CO1. (e) Mitochondrial translation products. Gels show loading controls (right) and electrophoretic patterns of
mitochondrial translation products (left) from patient (P) and control (C) fibroblasts. Gels of this figure have been cropped to improve the clarity and
conciseness of the presentation. See Supplementary Figure S3 for uncropped gel images.
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impact on patients’ care, on other family members who test negative
or positive for the false-positive variants and on future family
planning.9 Therefore, performing functional analysis on relevant cells
and validating the effect of variants by restoring the phenotype after
complementing the genetic deficiency are fundamental approaches to
define pathogenicity. In our case, the deficiency in activity of several
respiratory complexes with mtDNA-encoded subunits, the low p.MT-
CO1 levels, the altered mitochondrial protein synthesis, the EFTs
absence in patient fibroblasts and the correction of the biochemical
defect by overexpressing the wild-type EFTs confirm the EFTs
mutation as the etiologic factor explaining the phenotype of this
patient.
Two other previously described EFTs pathologic missense muta-
tions c.997C4T (p.(Arg312Trp)) and c.944G4A (p.(Cys315Tyr))
also located in subdomain C, but in the β6 strand, affect the
β-sandwich core, especially the contact surface for interaction with
EFTu (Figure 1c), and the levels of both factors are decreased
(Supplementary Table S1).3,10 Seven patients from five different
pedigrees harbored, in homozygosity, a EFTs (p.(Arg312Trp)) amino
acid substitution. Despite pulse labeling of mitochondrial translation
products only revealed a moderate reduction in mitochondrial protein
synthesis, all of these patients died of encephalomyopathy, hyper-
trophic cardiomyopathy or liver failure before the age of 2
months.10–12 Surprisingly, the patient here reported, presenting ataxia
and hypertrophic cardiomyopathy, was alive at the age of 23 years. His
mutation also decreased the EFTs levels, but the EFTu levels were
normal. However, mitochondrial translation was greatly decreased.
Very interestingly, itQ9 has recently been described an individual with
low EFTs but normal EFTu levels and a clear reduction in mitochon-
drial translation (Supplementary Table S1).3 This patient harbored
compound heterozygous EFTs mutations c.[856C4T];[106+4A4G].
He presented ataxia, optical and peripheral neuropathy, and was
also alive at the age of 21 years, but he did not show cardiomyopathy.3
In a different pedigree, two sisters harbored (p.(Cys315Tyr))/
(p.(Gln286Ter)) mutations, suffered from hypertrophic cardiomyo-
pathy and survived for 415 years. These patients had low levels of
both EFTs and EFTu, but mitochondrial translation was partially
decreased in one of them and unaffected in the other one.3 Thus, there
is no a clear correlation between EFTs/EFTu levels and mitochondrial
protein synthesis. Apparently, a large decrease in EFTu levels must
provoke a compensatory response that, in same degree, corrects the
mitochondrial translation defect. This defect is not corrected when
EFTu levels are not highly decreased. Although differences in EFTu
levels or mitochondrial translation are not related with the affected
organs and do not seem to be the reason for an extended survival, low
EFTs and EFTu levels appear to be associated with an early age
of onset.
More interestingly, it has been proposed that TSFM mutations can
provoke early developmental lethality.3 Thus, the three miscarriages
reported in this family could also be owing to this TSFM mutation
found in the index case, although we did not have the opportunity to
study these cases. Other factors would be responsible for the marked
differences between these four cases.
In summary, all data presented in this manuscript confirm that the
TSFM mutation here reported is the etiologic factor of the disease.
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